

Robert W Milne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4576170/publications.pdf>

Version: 2024-02-01

83
papers

5,291
citations

145106

33
h-index

93651

72
g-index

85
all docs

85
docs citations

85
times ranked

5907
citing authors

#	ARTICLE	IF	CITATIONS
1	Liposomal 5-Fluorouracil Polymer Complexes Facilitate Tumor-Specific Delivery: Pharmacokinetics and Pharmacodynamic Distribution Kinetics Using Microdialysis. <i>Pharmaceutics</i> , 2022, 14, 221.	2.0	4
2	An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 1113.	1.7	6
3	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113248.	2.6	13
4	CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. <i>Frontiers in Oncology</i> , 2021, 11, 678559.	1.3	62
5	A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 827-838.	0.6	9
6	Targeting CDK9 for treatment of colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2178-2193.	2.1	39
7	Sulfonamide-Based Inhibitors of Biotin Protein Ligase as New Antibiotic Leads. <i>ACS Chemical Biology</i> , 2019, 14, 1990-1997.	1.6	5
8	Bioanalysis and Stability of Polymyxins. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 73-87.	0.8	5
9	Discovery of CDK5 Inhibitors through Structure-Guided Approach. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 786-791.	1.3	18
10	CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. <i>Investigational New Drugs</i> , 2019, 37, 625-635.	1.2	26
11	Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity. <i>Medicinal Chemistry</i> , 2019, 15, 602-623.	0.7	7
12	Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. <i>British Journal of Pharmacology</i> , 2018, 175, 2399-2413.	2.7	18
13	Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00406.	1.1	3
14	Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-2-yl-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1892-1915.	2.9	55
15	Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study. <i>Drug Metabolism and Disposition</i> , 2017, 45, 569-575.	1.7	8
16	CDK5 in oncology: recent advances and future prospects. <i>Future Medicinal Chemistry</i> , 2017, 9, 1939-1962.	1.1	36
17	Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 762-772.	2.6	23
18	The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. <i>Environmental Research</i> , 2017, 158, 366-372.	3.7	35

#	ARTICLE	IF	CITATIONS
19	Targeting CDK9: a promising therapeutic opportunity in prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T211-T226.	1.6	57
20	Unveiling new chemical scaffolds as Mnk inhibitors. <i>Future Medicinal Chemistry</i> , 2016, 8, 271-285.	1.1	18
21	Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. <i>Oncotarget</i> , 2016, 7, 56811-56825.	0.8	20
22	The Association of Socio-Demographic Status, Lifestyle Factors and Dietary Patterns with Total Urinary Phthalates in Australian Men. <i>PLoS ONE</i> , 2015, 10, e0122140.	1.1	26
23	Targeting Pim kinases for cancer treatment: opportunities and challenges. <i>Future Medicinal Chemistry</i> , 2015, 7, 35-53.	1.1	35
24	Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. <i>Xenobiotica</i> , 2015, 45, 3-9.	0.5	3
25	MAP Kinase-Interacting Kinases—Emerging Targets against Cancer. <i>Chemistry and Biology</i> , 2014, 21, 441-452.	6.2	83
26	Discovery of 5-(Phenylamino)pyrimidin-2-thiazol-3-ylidene Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation. <i>ChemMedChem</i> , 2014, 9, 962-972.	1.6	67
27	Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study. <i>International Journal of Epidemiology</i> , 2014, 43, 1040-1053.	0.9	53
28	Discovery of 3-((Styrylsulfonyl)methyl)pyridine and 2-((Styrylsulfonyl)methyl)pyridine Derivatives as Anticancer Agents: Synthesis, Structure-Activity Relationships, and Biological Activities. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2275-2291.	2.9	23
29	Chiral Stability Study of Oral Liquid Clopidogrel Formulations for Infants. <i>Journal of Pharmacy Practice and Research</i> , 2012, 42, 106-110.	0.5	2
30	Stability of <i>Myrmecia pilosula</i> (Jack Jumper) Ant venom for use in immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 303-310.	1.4	12
31	PHARMACOKINETICS OF MOXIDECTIN IN THE SOUTHERN HAIRY-NOSED WOMBAT (<i>LASIORHINUS LATIFRONS</i>). <i>Journal of Wildlife Diseases</i> , 2011, 47, 643-649.	0.3	18
32	The effects of the phytoestrogenic isoflavone genistein on the hepatic disposition of preformed and hepatically generated gemfibrozil 1-O-acyl glucuronide in the isolated perfused rat liver. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1433-1439.	1.2	1
33	Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1641-1646.	1.2	9
34	The effects of phytoestrogenic isoflavones on the formation and disposition of paracetamol sulfate in the isolated perfused rat liver. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 639-646.	1.2	10
35	Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1037-1042.	1.2	0
36	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. <i>British Journal of Cancer</i> , 2010, 103, 597-606.	2.9	25

#	ARTICLE	IF	CITATIONS
37	Inhibition of Morphine Metabolism by Ketamine. <i>Drug Metabolism and Disposition</i> , 2010, 38, 728-731.	1.7	27
38	Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against <i>Pseudomonas aeruginosa</i> in Murine Thigh and Lung Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1117-1124.	1.4	178
39	Renal Disposition of Colistin in the Isolated Perfused Rat Kidney. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2857-2864.	1.4	68
40	Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 1037-1042.	1.2	6
41	<i>Myrmecia pilosula</i> (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 46, 58-65.	1.4	18
42	Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 862, 205-212.	1.2	54
43	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 347-354.	1.1	7
44	Subacute Toxicity of Colistin Methanesulfonate in Rats: Comparison of Various Intravenous Dosage Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1159-1161.	1.4	67
45	Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with <i>Pseudomonas aeruginosa</i> in an in vitro pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 636-642.	1.3	119
46	CYP2B6, CYP2D6, and CYP3A4 Catalyze the Primary Oxidative Metabolism of Perhexiline Enantiomers by Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2007, 35, 128-138.	1.7	25
47	Effect of CYP2D6 metabolizer status on the disposition of the (+) and (–) enantiomers of perhexiline in patients with myocardial ischaemia. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 305-312.	0.7	10
48	Original article: <i>Myrmecia pilosula</i> (Jack Jumper) ant venom: identification of allergens and revised nomenclature. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 437-443.	2.7	46
49	Isosteviol reduces plasma glucose levels in the intravenous glucose tolerance test in Zucker diabetic fatty rats. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 597-599.	2.2	50
50	Frequently asked questions about generic medicines. <i>Australian Prescriber</i> , 2007, 30, 41-43.	0.5	14
51	Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. <i>Lancet Infectious Diseases</i> , 2006, 6, 589-601.	4.6	1,170
52	Disposition and Metabolite Kinetics of Oral L-carnitine in Humans. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1163-1170.	1.0	34
53	Proteomic analysis of <i>Myrmecia pilosula</i> (jack jumper) ant venom. <i>Toxicon</i> , 2006, 47, 208-217.	0.8	41
54	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 832, 114-120.	1.2	17

#	ARTICLE	IF	CITATIONS
55	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 843, 302-309.	1.2	12
56	Loading-Washout Studies of the Stereoselective Sinusoidal Uptake of (R)- and (S)-2-Phenylpropionyl Acyl Glucuronide. <i>Current Drug Metabolism</i> , 2006, 7, 817-826.	0.7	0
57	Oral L-Carnitine: Metabolite Formation and Hemodialysis. <i>Current Drug Metabolism</i> , 2006, 7, 811-816.	0.7	24
58	Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1300-1304.	0.4	222
59	Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 11-25.	1.1	456
60	Stereoselective Hepatic Disposition of Model Diastereomeric Acyl Glucuronides. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2004, 31, 1-27.	0.8	3
61	The quantification of paracetamol, paracetamol glucuronide and paracetamol sulphate in plasma and urine using a single high-performance liquid chromatography assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004, 34, 585-593.	1.4	80
62	Quantifying trimethylamine and trimethylamine-N-oxide in human plasma: interference from endogenous quaternary ammonium compounds. <i>Analytical Biochemistry</i> , 2004, 334, 403-405.	1.1	26
63	Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 837-840.	1.3	150
64	Phenytoin Infusion Revisited: Stability and Administration. <i>Journal of Pharmacy Practice and Research</i> , 2004, 34, 272-275.	0.5	1
65	Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1766-1770.	1.4	149
66	Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid Chromatography. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1364-1370.	1.4	182
67	Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions. <i>British Journal of Anaesthesia</i> , 2003, 90, 750-758.	1.5	15
68	Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 987-992.	1.3	159
69	Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid Chromatography. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3304-3307.	1.4	101
70	A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001, 761, 167-175.	1.7	131
71	A small-scale synthesis and enantiomeric resolution of (RS)-[1-14C]-2-Phenylpropionic acid and biosynthesis of its diastereomeric acyl glucuronides. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2001, 44, 225-234.	0.5	8
72	In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 781-785.	1.4	218

#	ARTICLE	IF	CITATIONS
73	Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. <i>Pharmaceutical Research</i> , 2000, 17, 1511-1515.	1.7	38
74	Organ perfusion techniques in drug development. <i>Drug Development Research</i> , 1999, 46, 292-301.	1.4	10
75	Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig. <i>Pharmaceutical Research</i> , 1997, 14, 1014-1018.	1.7	18
76	The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans and Animals, and the Importance of the Metabolites to the Pharmacological Effects of Morphine. <i>Drug Metabolism Reviews</i> , 1996, 28, 345-472.	1.5	190
77	Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. <i>Clinical Pharmacokinetics</i> , 1993, 24, 413-420.	1.6	44
78	High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. <i>Biomedical Applications</i> , 1991, 565, 457-464.	1.7	78
79	PHYSIOLOGICAL DISPOSITION OF I.V. MORPHINE IN SHEEP â€. <i>British Journal of Anaesthesia</i> , 1991, 67, 378-386.	1.5	20
80	Pharmacokinetic Drug Interactions with Phenytoin (Part I)1. <i>Clinical Pharmacokinetics</i> , 1990, 18, 37-60.	1.6	112
81	Pharmacokinetic Drug Interactions with Phenytoin (Part II). <i>Clinical Pharmacokinetics</i> , 1990, 18, 131-150.	1.6	46
82	Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration. <i>Antimicrobial Agents and Chemotherapy</i> , 1985, 28, 293-298.	1.4	7
83	Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets. <i>European Journal of Clinical Pharmacology</i> , 1979, 16, 417-421.	0.8	6